Followup to this post: A US District Court has ruled that Myriad Genetic's patents on breast cancer genes BRCA1 and BRCA2, which allow them to hold exclusive rights to a widely used genetic test for inherited breast and ovarian cancer susceptibility, are invalid. Genomics Law Report analyzes the ruling in two posts. The decision is likely to be challenged in a legal appeal — but if upheld, it could have huge implications for the biotechnology industry. [more inside]
posted by zarq
on Mar 31, 2010 -
51 comments
Scientists have created a miniature medical computer out of DNAthat can detect cancer genes in a test tube and respond by releasing a drug.
However, an injectable version [of the nanoscale robots] would have to work inside cells, and that accomplishment could take decades. Says Shapiro: "I'm not sure it will be within my lifetime."
posted by mcgraw
on May 5, 2004 -
11 comments